Hormone may help fight obesity and reduce cholesterol

September 3, 2013

Research has shown that giving obese rodents a recently identified circulating protein called fibroblast growth factor 21 (FGF21) helps improve their metabolism. Now investigators reporting in the Cell Press journal Cell Metabolism reveal that a variant of FGF21 has similar effects in obese people with type 2 diabetes.

"Our findings suggest that FGF21 has the ability to favorably affect body weight and to partially normalize abnormal lipid levels in patients with diabetes. These are substantial issues and unmet medical needs for patients with obesity and ," says senior author Dr. David Moller, vice president of endocrine and cardiovascular research at Eli Lilly and Company.

Lilly scientists initially identified FGF21 as a novel target for its potential in treating metabolic disorders. Dr. Moller and his colleagues studied the effects of LY2405319 (LY), a variant of FGF21, in a randomized, placebo-controlled, double-blind proof-of-concept trial in 46 patients with obesity and type 2 diabetes. LY treatment led to decreases in LDL cholesterol and triglycerides, increases in HDL cholesterol, and decreases in atherosclerosis-causing lipoproteins.

LY also reduced body weight and fasting insulin, and it increased adiponectin, a hormone produced by that may augment insulin's effects. While there was only a slight lowering of in patients treated with LY, the study's results indicate that FGF21 is active in humans and suggest that FGF21-based therapies may be effective for treating metabolic disorders.

"We are encouraged by the potential of FGF21 to produce multiple metabolic effects in people with diabetes and are evaluating further concepts for FGF21-based therapies," says Dr. Moller. He notes that most people with diabetes have other risk factors related to metabolic syndrome, including , abdominal obesity, elevated triglycerides, low HDL cholesterol levels, and hypertension. No currently available treatment is able to address more than one of these conditions. "Thus, combination therapy is usually prescribed and often leads to tolerability issues, poor patient compliance, and suboptimal outcomes, all of which provide an incentive to continue the search for new therapeutic approaches," Dr. Moller explains.

Explore further: FGF21 hormone, key to control obesity, also protects against heart diseases in mice

More information: Cell Metabolism, Gaich et al.: "The Effects of LY2405319, an FGF21 Analog, in Obese Human Subjects with Type 2 Diabetes." dx.doi.org/10.1016/j.cmet.2013.08.005

Related Stories

FGF21 hormone, key to control obesity, also protects against heart diseases in mice

June 18, 2013
A research group has found that FGF21, an endocrine factor which reduces glucose levels, protects against cardiac diseases in mice. The research, published online on the journal Nature Communications, was led by Francesc ...

New treatment aids weight loss, improves diabetes in monkeys

November 28, 2012
(HealthDay)—A new, lab-created antibody that mimics the action of a naturally occurring molecule causes weight loss in monkeys, researchers report.

Antibody injection promising for diabetes and obesity

December 16, 2011
(Medical Xpress) -- Researchers at Genetech Inc. in South San Francisco, California, led by molecular biologist Junichiro Sonoda, have discovered that a single injection of antibodies into obese diabetic mice provided a marked ...

Recommended for you

Want to win at sports? Take a cue from these mighty mice

July 20, 2017
As student athletes hit training fields this summer to gain the competitive edge, a new study shows how the experiences of a tiny mouse can put them on the path to winning.

'Smart' robot technology could give stroke rehab a boost

July 19, 2017
Scientists say they have developed a "smart" robotic harness that might make it easier for people to learn to walk again after a stroke or spinal cord injury.

Engineered liver tissue expands after transplant

July 19, 2017
Many diseases, including cirrhosis and hepatitis, can lead to liver failure. More than 17,000 Americans suffering from these diseases are now waiting for liver transplants, but significantly fewer livers are available.

Lunatic Fringe gene plays key role in the renewable brain

July 19, 2017
The discovery that the brain can generate new cells - about 700 new neurons each day - has triggered investigations to uncover how this process is regulated. Researchers at Baylor College of Medicine and Jan and Dan Duncan ...

New animal models for hepatitis C could pave the way for a vaccine

July 19, 2017
They say that an ounce of prevention is worth a pound of cure. In the case of hepatitis C—a disease that affects nearly 71 million people worldwide, causing cirrhosis and liver cancer if left untreated—it might be worth ...

Omega-3 fatty acids fight inflammation via cannabinoids

July 18, 2017
Chemical compounds called cannabinoids are found in marijuana and also are produced naturally in the body from omega-3 fatty acids. A well-known cannabinoid in marijuana, tetrahydrocannabinol, is responsible for some of its ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

IJ Coleman
not rated yet Sep 04, 2013
I much prefer using the new options under my insurance: http://navixmarke...amacare/

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.